Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur
A phase 2 trial of Cyclophosphamide, Pembrolizumab in ovarian cancer and hepatocellular carcinoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), active and no longer recruiting.
Overview
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors is a phase 2 interventional study registered as NCT03836352 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 184 participants planned, started 2018-12-21 and due to reach its primary completion in 2023-12-31. Interventions recorded: DPX-Survivac, Cyclophosphamide, Pembrolizumab. Conditions listed: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Shares Cyclophosphamide, Ovarian cancer.
- TrialPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Shares Cyclophosphamide, Ovarian cancer, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp
Shares Cyclophosphamide, Pembrolizumab.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Cyclophosphamide, Hepatocellular carcinoma.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Cyclophosphamide, Ovarian cancer.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Shares Cyclophosphamide, Pembrolizumab.
- TrialA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Shares Cyclophosphamide, Pembrolizumab.
- TrialA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Shares Cyclophosphamide, Pembrolizumab.